Received approval by the USFDA.
Leading global pharmaceutical company Dr. Reddy’s Laboratories Ltd. announced on Thursday that it has launched Aripiprazole tablets used in the treatment of patients with schizophrenia and bipolar disorder, in the US market.
The therapeutic equivalent generic version of Ablify tablets received approval of the US Food and Drug Administration (USFDA), said reports.
Abilify is a registered trademark of Otsuka Pharmaceutical Company, Japan which had U.S. sales of approximately $3.1 billion MAT for the most recent twelve months ending in August 2016 according to IMS Health, said a statement released by Dr. Reddy’s Laboratories.
The company with presence in 26 countries had announced its entry into Colombia with its portfolio of high quality and affordable medicines for cancer patients on October 7. Reddy’s Colombian operation was formally launched by M.V. Ramana, Executive Vice President and Head, Branded Markets, Global Generics.
On Monday this week, Dr. Reddy’s announced the launch of Lamotrigine Orally Disintegrating Tablets, a therapeutic equivalent generic version of Lamictal® ODT (lamotrigine) Orally Disintegrating Tablets in the United States market.
Over the years, Dr. Reddy’s has become a trusted provider of medicines around the world. It is today the 2nd largest Generic Oncology Injectable Company by value in the U.S. and the No. 1 Generic Oncology Company in India.
In November last year, the company had received a “warning” letter” from the U.S. Food and Drug Administration over inadequate quality controls at three manufacturing plants producing drugs for cancer and other diseases.